REVIEW ARTICLE
BJD
British Journal of Dermatology
Network meta-analysis of the outcome ‘participant
complete clearance’ in nonimmunosuppressed participants
of eight interventions for actinic keratosis: a follow-up on a
Cochrane review
A.K. Gupta
1,2
and M. Paquet
2
1
Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
2
Mediprobe Research Inc., London, ON, Canada
Correspondence
Aditya K. Gupta.
E-mail: agupta@execulink.com
Accepted for publication
21 March 2013
Funding sources
None.
Conflicts of interest
None declared.
DOI 10.1111/bjd.12343
Summary
The conclusions of pairwise meta-analyses of interventions for actinic keratosis
(AK) are limited due to the lack of direct comparison between some interventions.
Consequently, we performed a network meta-analysis for eight treatments [5-amino-
laevulinic acid (ALA)-photodynamic therapy (PDT), cryotherapy, diclofenac 3%
in 25% hyaluronic acid (DCF/HA), 5-fluorouracil (5-FU) 05% or 50%, imiqui-
mod (IMI) 5%, ingenol mebutate (IMB) 0015–005%, methyl aminolaevulinate
(MAL)-PDT and placebo/vehicle (including placebo-PDT)] to determine their rel-
ative efficacies. As part of a prior Cochrane systematic review, different databases
and grey literature were searched for randomized controlled trials up to April
2012. The inclusion criteria were parallel-group studies with nonimmunosup-
pressed participants: (i) reporting ‘participant complete clearance’ and (ii) com-
paring at least two of the interventions. Thirty-two publications met the criteria
and they included the following number of individual or pooled studies (n) and
total number of participants (N) for the different interventions: 5-FU 05%
(n = 4, N = 169), 5-FU 50% (n = 2, N = 44), ALA-PDT (n = 6, N = 739), cryo-
therapy (n = 2, N = 174), DCF/HA (n = 5, N = 299), IMI (n = 14, N = 1411),
IMB (n = 3, N = 560), MAL-PDT (n = 7, N = 557) and placebo (n = 32,
N = 2520). Network analyses using a random-effects Bayesian model were carried
out with the software ADDIS v1.16.1. The interventions were ranked as follows
based on calculated probabilities and odd ratios: 5-FU > ALA-PDT IMI IMB
MAL-PDT > cryotherapy > DCF/HA > placebo. This efficacy ranking was
obtained based on the current available data on ‘participant complete clearance’
from randomized controlled trials and the analysis model used. However, several
other factors should also be considered when prescribing a treatment for AK.
What’s already known about this topic?
•
Several interventions are effective for the treatment of actinic keratosis (AK).
•
Due to the lack of direct comparisons between these interventions, their relative
efficacy is unknown.
What does this study add?
•
Using network meta-analysis, the relative efficacy of eight main interventions for
AK was determined based on the outcome ‘participant complete clearance’.
•
With the exception of ingenol mebutate, the relative efficacy of the interventions
was independent of the anatomical location of the lesions.
© 2013 Mediprobe Research Inc
BJD © 2013 British Association of Dermatologists
250 British Journal of Dermatology (2013) 169, pp250–259